Michael N. Dudley

Best Publications

• Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update

  Johan W. Mouton;Michael N. Dudley;Otto Cars;Hartmut Derendorf

  645
  Citations

• Discovery of a Cyclic Boronic Acid β-Lactamase Inhibitor (RPX7009) with Utility vs Class A Serine Carbapenemases.

  Hecker Sj;Reddy Kr;Totrov M;Hirst Gc

  428
  Citations

• Effect and Safety of Meropenem–Vaborbactam versus Best-Available Therapy in Patients with Carbapenem-Resistant Enterobacteriaceae Infections: The TANGO II Randomized Clinical Trial

  Richard G. Wunderink;Evangelos J. Giamarellos-Bourboulis;Galia Rahav;Amy J. Mathers

  416
  Citations

• Framework for optimisation of the clinical use of colistin and polymyxin B : the Prato polymyxin consensus

  Roger Leigh Nation;Jian Li;Otto Cars;William Couet

  399
  Citations

• Vaborbactam: Spectrum of Beta-Lactamase Inhibition and Impact of Resistance Mechanisms on Activity in Enterobacteriaceae

  Olga Lomovskaya;Dongxu Sun;Debora Rubio-Aparicio;Kirk Nelson

  394
  Citations

• Effect of Meropenem-Vaborbactam vs Piperacillin-Tazobactam on Clinical Cure or Improvement and Microbial Eradication in Complicated Urinary Tract Infection: The TANGO I Randomized Clinical Trial.

  Keith S. Kaye;Tanaya Bhowmick;Symeon Metallidis;Susan C. Bleasdale

  352
  Citations

• Application of a mathematical model to prevent in vivo amplification of antibiotic-resistant bacterial populations during therapy

  Nelson Jumbe;Arnold Louie;Robert Leary;Weiguo Liu

  324
  Citations

• Multiple Resistance Mechanisms among Aspergillus fumigatus Mutants with High-Level Resistance to Itraconazole

  Adriana M. Nascimento;Gustavo H. Goldman;Steven Park;Salvatore A. E. Marras

  314
  Citations

• 2′,3′-Didehydro-3′-deoxythymidine (d4T) in Patients with AIDS or AIDS-Related Complex: A Phase I Trial

  Marcia J. Browne;Kenneth H. Mayer;Stephanie B. D. Chafee;Michael N. Dudley

  240
  Citations

• Application of a mathematical model to prevent in vivo amplification of antibiotic-resistant bacterial populations during therapy

  Unknown

  234
  Citations

• Discovery of Cyclic Boronic Acid QPX7728, an Ultra-broad-spectrum Inhibitor of Serine and Metallo Beta-lactamases.

  Scott J. Hecker;K. Raja Reddy;Olga Lomovskaya;David C. Griffith

  218
  Citations

• Meropenem-Vaborbactam Resistance Selection, Resistance Prevention, and Molecular Mechanisms in Mutants of KPC-Producing Klebsiella pneumoniae.

  Dongxu Sun;Debora Rubio-Aparicio;Kirk Nelson;Michael N. Dudley

  189
  Citations

• Oral bacitracin vs vancomycin therapy for Clostridium difficile-induced diarrhea. A randomized double-blind trial.

  Michael N. Dudley;James C. McLaughlin;George Carrington;Jean Frick

  186
  Citations

• Background and rationale for revised clinical and laboratory standards institute interpretive criteria (Breakpoints) for Enterobacteriaceae and Pseudomonas aeruginosa: I. Cephalosporins and Aztreonam.

  Michael N Dudley;Paul G Ambrose;Sujata M Bhavnani;William A Craig

  183
  Citations

• A synthetic lipopeptide targeting top-priority multidrug-resistant Gram-negative pathogens

  Unknown

  183
  Citations

• Pharmacodynamics and pharmacokinetics of antibiotics with special reference to the fluoroquinolones.

  Unknown

  172
  Citations

• Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs.

  Johan W Mouton;Michael N Dudley;Otto Cars;Hartmut Derendorf

  153
  Citations

• Predicting efficacy of antiinfectives with pharmacodynamics and Monte Carlo simulation.

  John S Bradley;Michael N Dudley;George L Drusano

  151
  Citations

• In Vitro Activity of Meropenem-Vaborbactam against Clinical Isolates of KPC-Positive Enterobacteriaceae.

  Meredith A. Hackel;Olga Lomovskaya;Michael N. Dudley;James A. Karlowsky

  149
  Citations

• Interactions of Fluoroquinolones with Other Drugs: Mechanisms, Variability, Clinical Significance, and Management

  Unknown

  144
  Citations